European Journal of Nuclear Medicine and Molecular Imaging

, Volume 33, Issue 11, pp 1352–1363

Auger radiation targeted into DNA: a therapy perspective

Authors

    • Service of Nuclear MedicineUniversity Hospital of Lausanne CHUV
    • Service of Nuclear MedicineUniversity Hospital of Lausanne
  • Florence Perillo-Adamer
    • Service of Nuclear MedicineUniversity Hospital of Lausanne CHUV
  • Yves M. Dupertuis
    • Service of NutritionUniversity Hospital of Geneva
  • Angelika Bischof Delaloye
    • Service of Nuclear MedicineUniversity Hospital of Lausanne CHUV
Review article

DOI: 10.1007/s00259-006-0187-2

Cite this article as:
Buchegger, F., Perillo-Adamer, F., Dupertuis, Y.M. et al. Eur J Nucl Med Mol Imaging (2006) 33: 1352. doi:10.1007/s00259-006-0187-2

Abstract

Background

Auger electron emitters that can be targeted into DNA of tumour cells represent an attractive systemic radiation therapy goal. In the situation of DNA-associated decay, the high linear energy transfer (LET) of Auger electrons gives a high relative biological efficacy similar to that of α particles. In contrast to α radiation, however, Auger radiation is of low toxicity when decaying outside the cell nucleus, as in cytoplasm or outside cells during blood transport. The challenge for such therapies is the requirement to target a high percentage of all cancer cells. An overview of Auger radiation therapy approaches of the past decade shows several research directions and various targeting vehicles. The latter include hormones, peptides, halogenated nucleotides, oligonucleotides and internalising antibodies.

Discussion

Here, we will discuss the basic principles of Auger electron therapy as compared with vector-guided α and β radiation. We also review some radioprotection issues and briefly present the main advantages and disadvantages of the different targeting modalities that are under investigation.

Keywords

Auger radiation Nuclear targeting Treatment Dosimetry

Copyright information

© Springer-Verlag 2006